If the float was chewed up today, which appears to be the case given the leapfrogging of stock price noticeable from above 0.0200 to the 0.0329 high, then a new higher floor has been set. That would argue for a much tighter supply of stock below 0.0200. The cheapies are gone. As D-Day for Invasion of the Dharmanol rapidly approaches, SKTO should be closing in on .04.
The chart says SKTO climbed to .06 on more or less nothing (March 2013).
That was before Berkeley Bio (Gold Standard of Game-Changing Medical Cannabis Products),
and before the ground-breaking Dharmanol was ready to be shipped,
and before the T-Hydrocan line was next up with other products in pipeline,
and before "over 400 collectives" were participating with MG,
and before numerous CA growers were recruited to fill demand for MG/BB products,
and before a 20-state count legalizing MMJ, and before CO and WA legalized recreational MJ,
and before feds backed off medical cannabis, and before recent news of 12,000 sq ft. indoor grow facility exclusively dedicated to filling demand for MG/BB products,
and before reports from beta testers praising Dharmanol's health-infusing and becalming effects,
and before all-natural dietary supplement Dharmanol, seen as an anti-cancer option and powerful immune booster, was also seen as possible competion for Valium and Xanax and perhaps Ritalin along with a host of other Pharma drugs.
Therefore, at 0.02 with $12m market cap, there's plenty of room for SKTO to run.
The chart says SKTO climbed to .06 on more or less nothing (March 2013).
That was before Berkeley Bio (Gold Standard of Game-Changing Medical Cannabis Products),
and before the ground-breaking Dharmanol was ready to be shipped,
and before the T-Hydrocan line was next up with other products in pipeline,
and before "over 400 collectives" were participating with MG,
and before numerous CA growers were recruited to fill demand for MG/BB products,
and before a 20-state count legalizing MMJ, and before CO and WA legalized recreational MJ,
and before feds backed off medical cannabis, and before recent news of 12,000 sq ft. indoor grow facility exclusively dedicated to filling demand for MG/BB products,
and before reports from beta testers praising Dharmanol's health-infusing and becalming effects,
and before all-natural dietary supplement Dharmanol, seen as an anti-cancer option and powerful immune booster, was also seen as possible competion for Valium and Xanax and perhaps Ritalin along with a host of other Pharma drugs.
Therefore, at 0.02 with $12m market cap, there's plenty of room for SKTO to run.
